Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2025-12-25 @ 2:44 AM
NCT ID:
NCT03188133
Eligibility Criteria:
All Groups:
* Age between 18 and 55 years
* Affiliation to or benefiting from a social security
* Visual acuity normal or corrected to normal
* Person who received and understood the complete information about the organization of the research and gave written and free informed consent before participating in the study
Group of patients with schizophrenia with visual hallucination (HV) with or without auditory hallucination (HA) (HV group):
* Schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders IV criteria
* Presence of a hallucinatory visual symptomatology (HV) in the history of the disease measured by the Psychosensory hallucination scale (PSAS).
* The presence of a hallucinatory symptomatology in auditory mode (HA) in addition to the HV is not a criterion of non-inclusion.
Group of patients with schizophrenia either with auditory hallucination (HA) but without visual hallucination (HV) or no hallucination, auditory or visual (NH) (HA / NH group)
* Schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders IV criteria
* Presence of a hallucinatory symptomatology in auditory mode (HA) in the history of the disease measured by the PSAS or absence of any hallucinatory manifestations in the history of the disease
* Absence of visual hallucinatory symptomatology (HV) in the history of the disease as measured by PSAS
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT03188133
Study Brief:
Protocol Section:
NCT03188133